AstraZeneca Takes Drug-Price Negotiation Suit to Third Circuit

AstraZeneca PLC is taking its challenge against a government drug price-setting scheme to a federal appeals court.

The diabetes drugmaker on Monday filed notice for its appeal to the US Court of Appeals for the Third Circuit after the dismissal of its case against the Medicare Drug Price Negotiation Program.

Chief Judge Colm F. Connolly of the US District Court for the District of Delaware on March 1 ruled AstraZeneca didn’t have Article 3 standing to challenge the lawfulness of the government’s scheme and “has not identified a property interest protected by the Constitution that is put in jeopardy by ...